Key terms
About OVID
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OVID news
Apr 05
9:38am ET
Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
Apr 05
4:42am ET
Ovid initiated with Outperform on ‘unique’ assets at Wedbush
Apr 04
4:19pm ET
Ovid Therapeutics initiated with an Outperform at Wedbush
Mar 27
8:50am ET
Marinus Comments on patent challenge by Ovid Therapeutics
Mar 12
6:45am ET
Ovid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic Partnerships
Mar 10
10:55pm ET
TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)
Mar 08
8:06am ET
Ovid Therapeutics reports Q4 EPS (22c), consensus (5c)
Feb 21
5:55am ET
Ovid Therapeutics management to meet with Oppenheimer
Feb 20
4:55am ET
Ovid Therapeutics management to meet with Oppenheimer
Feb 15
8:38am ET
Ovid Therapeutics management to meet with Oppenheimer
Feb 14
4:55am ET
Ovid Therapeutics management to meet with Oppenheimer
Feb 12
4:55am ET
Ovid Therapeutics management to meet with Oppenheimer
Feb 05
7:32am ET
Ovid Therapeutics management to meet with Oppenheimer
Jan 07
5:40am ET
BTIG Sticks to Its Buy Rating for Ovid Therapeutics (OVID)
No recent press releases are available for OVID
OVID Financials
Key terms
Ad Feedback
OVID Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OVID Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
